Agios Pharmaceuticals, Inc. (AGIO) Investor Relations Documents

Agios Pharmaceuticals, Inc. (AGIO) investor relations documents from the company's IR site: 3 presentations, 36 press releases; latest deck 2026-06-13. Read in-app with summaries. First-party data.

EHA 2026 Investor Webcast Presentation_FINAL.pdf: Agios Pharmaceuticals' EHA 2026 presentation highlights mitapivat's clinical efficacy in thalassemia and sickle cell disease, alongside its broader hematology pipeline.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-30Press releasePDF Version
2026-07-30Press releaseAgios Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-21Press releaseAgios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
2026-07-07Press releaseU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
2026-06-29Press releaseAgios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
2026-06-13Press releaseAgios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapiv
2026-06-13PresentationEHA 2026 Investor Webcast Presentation_FINAL.pdf
2026-06-10DocumentPDF Version
2026-06-08Press releasePDF Version
2026-06-01Press releaseAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor
2026-05-29Press releaseAgios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
2026-05-22Press releaseAgios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
2026-05-12Press releaseAgios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
2026-05-12Press releaseAgios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare H
Press releaseAgios Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-06Press releasePDF Version
2026-03-31Press releasePDF Version
2026-03-31Press releaseAgios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting wi
2026-03-02Press releasePDF Version
2026-03-02Press releaseAgios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
2026-02-12Press releaseAgios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-01-26Press releasePDF Version
2026-01-14Presentation44th Annual J.P. Morgan Healthcare Conference Presentation
2026-01-12Press releasePDF Version
2026-01-12Press releaseAgios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
2026-01-05Press releasePDF Version
2026-01-05Press releaseAgios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
2025-12-23Press releasePDF Version
2025-12-23Press releaseU.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
2025-12-08Press releasePDF Version
2025-12-08Press releaseAgios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
2025-11-19Press releasePDF Version
2025-11-19Press releaseAgios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
2025-11-03Press releasePDF Version
2025-10-30Press releasePDF Version
2025-10-29Earnings deckThird Quarter 2025 Financial Results Presentation
2025-10-17Press releasePDF Version
2025-10-17Press releaseAgios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
2025-10-16Press releasePDF Version
2025-09-04Press releasePDF Version

AGIO overview · AGIO earnings · AGIO financials · AGIO KPIs · AGIO documents · AGIO ownership · AGIO peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.